11/01/2019 12:00:00

Vivos Inc. Announces Expanded Applications of IsoPet® for Veterinary Cancer Therapy

Richland WA, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTCPINK: RDGL), announced that the device classification obtained from the FDA Center for Veterinary Medicine (CVM) is not limited to canine and feline sarcomas, and can be extended to a much broader population of veterinary cancers, essentially all solid tumors in animals.

A review by the international law firm, Hogan-Lovells, who are premier experts on FDA matters, confirmed the broader application of the FDA’s veterinary device classification. While the FDA does not have premarket authority over veterinary devices (i.e., products classified as a device can be brought to market without first being reviewed by the FDA) the manufacturer is responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.

It is the company’s responsibility to maintain a strict configuration control of the product and product labeling, including applicable indications for use, to stay within the bounds of the FDA regulations. We have prepared a formal Memorandum to File to document our systematic interpretation of the regulations and our disciplined process for assuring compliance with FDA requirements.

Dr. Mike Korenko, Vivos Inc CEO stated “With this significant development we are confident that there are no regulatory obstacles to treating a wide range of tumors in animals. We intend to continue with our strategy of partnering with university veterinary hospitals to generate additional data on the safety and effectiveness of IsoPet® therapy in order to enhance the confidence of the veterinary medicine community. We will also ensure that future users obtain our certified training to administer IsoPet® according to the procedures defined in our product labeling.”

About Vivos Inc. (OTC: RDGL)

Vivos, Inc. is a pharmaceutical company researching and developing minimally invasive treatments to combat cancer in humans and animals. It has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at the University of Missouri is currently underway.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for premarket clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.

Michael K. Korenko, President & CEO

MKorenko@RadioGel.com

Logo new.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Mar
I:SP500
Hejsa Lidt forårs opdatering. Langsigtet konjunkturmodel: Nederst kan I se den langsigtede konjunktu..
61
13 Mar
 
Skam dig selv. Jeg synes faktisk dit udsagn er urimeligt. Vedkommende har i god tro købt lidt aktier..
15
18 Mar
GOMX
SAS's emmision overtegnet så de regner med 15MUSD i provenu samlet - godt nyt for GOMSpace hvis de k..
14
14 Mar
BA
Elliot.Blot for info så har jeg cirka 14.000 timer på 737 serien og der er altid problemer når en ty..
14
19 Mar
VELO
  Studiet er et randomiseret fase 4 forsøg, hvor man sammenligner forlænget frigivelse Envarsus XR (..
12
14 Mar
DANSKE
Danske Bank er sværd at værdiansætte set i forhold til den situation som Danske Bank befinder sig i...
12
13 Mar
ZEAL
Der er nogle enkelt punkter som jeg har noteret mig under læsningen af Årsrapporten 2018 samt de sen..
12
09:12
ZEAL
Jeg skrev til IR vedr. lidt forskelligt, her er deres svar:  Bliver der afholdt en Capital Market D..
11
18 Mar
BAVA
For mig virker det ret underligt at udmelding fra FDA om ydereligere 3mdr mere behandlingstid bliver..
11
15 Mar
PNDORA
Det forhold, at Pandora på trods af negativ analyse fra Carnegie og udbetaling af udbytte har holdt ..
11

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Health Insurance, Conagra, Kraft Heinz, and Diplomat and Encourages Investors to Contact the Firm
2
PDAC welcomes Federal Budget 2019
3
PureCircle Launches Next Generation Stevia Leaf Sweeteners in Singapore
4
NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock
5
Dermira Prices $130.0 Million Public Offering of Common Stock

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 March 2019 20:07:16
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190320.1 - EUROWEB6 - 2019-03-20 21:07:16 - 2019-03-20 20:07:16 - 1000 - Website: OKAY